Cargando…
Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections
The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868068/ https://www.ncbi.nlm.nih.gov/pubmed/35203807 http://dx.doi.org/10.3390/antibiotics11020204 |
_version_ | 1784656175508226048 |
---|---|
author | Kowalski, Regis P. Nayyar, Shannon V. Romanowski, Eric G. Jhanji, Vishal |
author_facet | Kowalski, Regis P. Nayyar, Shannon V. Romanowski, Eric G. Jhanji, Vishal |
author_sort | Kowalski, Regis P. |
collection | PubMed |
description | The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no anti-infective susceptibility standards to interpret treatment success, but the systemic standards can be used to guide ocular therapy if the concentration of anti-infective in the ocular tissue is assumed to be higher than the concentration in the blood serum. This Perspective describes: (1) eye infections, (2) diagnostics of eye infections, (3) anti-infective treatment of eye infections, (4) anti-infective resistance of ocular pathogens, and (5) alternative anti-infective delivery and therapy. The data, based on years of clinical and laboratory research, support the premise that ocular infections are less problematic if etiologic agents are laboratory-diagnosed and if prompt, potent, anti-infective therapy is applied. Anti-infective susceptibility should be monitored to assure continued therapeutic success and the possibility of new-found resistance. New delivery systems and therapies may be helpful to better treat future ocular infections. |
format | Online Article Text |
id | pubmed-8868068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88680682022-02-25 Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections Kowalski, Regis P. Nayyar, Shannon V. Romanowski, Eric G. Jhanji, Vishal Antibiotics (Basel) Perspective The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no anti-infective susceptibility standards to interpret treatment success, but the systemic standards can be used to guide ocular therapy if the concentration of anti-infective in the ocular tissue is assumed to be higher than the concentration in the blood serum. This Perspective describes: (1) eye infections, (2) diagnostics of eye infections, (3) anti-infective treatment of eye infections, (4) anti-infective resistance of ocular pathogens, and (5) alternative anti-infective delivery and therapy. The data, based on years of clinical and laboratory research, support the premise that ocular infections are less problematic if etiologic agents are laboratory-diagnosed and if prompt, potent, anti-infective therapy is applied. Anti-infective susceptibility should be monitored to assure continued therapeutic success and the possibility of new-found resistance. New delivery systems and therapies may be helpful to better treat future ocular infections. MDPI 2022-02-06 /pmc/articles/PMC8868068/ /pubmed/35203807 http://dx.doi.org/10.3390/antibiotics11020204 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Kowalski, Regis P. Nayyar, Shannon V. Romanowski, Eric G. Jhanji, Vishal Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections |
title | Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections |
title_full | Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections |
title_fullStr | Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections |
title_full_unstemmed | Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections |
title_short | Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections |
title_sort | anti-infective treatment and resistance is rarely problematic with eye infections |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868068/ https://www.ncbi.nlm.nih.gov/pubmed/35203807 http://dx.doi.org/10.3390/antibiotics11020204 |
work_keys_str_mv | AT kowalskiregisp antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections AT nayyarshannonv antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections AT romanowskiericg antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections AT jhanjivishal antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections |